Post by
rgonlyfactspls on Apr 01, 2015 1:52pm
Must be April Fools' Day?!?...
Makes no sense to me why there would not be more interest in TST (in a positive way) after the Bristol Conference call. - Was a pleasant surprise to hear the cost per dose is now estimated to be potentially "north of $4,000". That has been revised up by 33%+ since the AGM when it was quoted at $3,000/dose. - Was also very interesting to hear the significance of the "median duration of 33 months". - Presentation was made with a quiet confidence. Liked pretty much all I heard. - However, MAYBE more investors need to be aware of the new Telesta story?!? Still waaaaaiting for the launch of a meaningful PR campaign. rg
Comment by
ChiefCommander1 on Apr 01, 2015 2:12pm
This post has been removed in accordance with Community Policy
Comment by
loveshackdave on Apr 01, 2015 3:04pm
The target of this presentation is institutional investors. I wouldn't think that they won't just buy immediately after hearing this presentation. If they are interested, they probably have some research to do before they start buying and affecting the SP.
Comment by
DamnYankees on Apr 01, 2015 3:54pm
I was expecting more. This is a submission stage cancer drug valued below 50 mil, which has publicly stated that they are reviewing multiple offers from multiple partners. Surely you would expect there to be some immediate uptake when a partership, sale or BLA submission could happen any day. Instead the SP retreats on weak volume.
Comment by
loveshackdave on Apr 01, 2015 4:36pm
The market cap is above $50M I'll have you know! SP is up nearly 20% in a month where IBB is at barely break even. Today's pullback will be recovered soon.
Comment by
loveshackdave on Apr 01, 2015 5:11pm
It seems to me that the TSE is a more reliable indicator of the actual market cap than the OTC since volume is over 4x higher on that exchange but either way, you're right it's still under $50M USD, barely. At any rate, I doubt there will be much of a divergence between the SP on the two for long.